SLC5A2 and diabetes mellitus: A recent meta-analysis of randomized controlled trials designed to determine correlation between SGLT-2 inhibitors and the incidence of DR proved a significant reduction of DR risk in patients treated with SGLT-2 inhibitors with diabetes duration of less than 10 years, which confers its potential value in early treatment initiation [84].